You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
亚盛医药-B(06855.HK)与UNITY Biotechnology合作获得里程碑付款
格隆汇 12-22 18:05

格隆汇 12 月 22日丨亚盛医药-B(06855.HK)发布公告,公司全球战略合作伙伴UNITY Biotechnology(UNITY,NASDAQ: UBX)在研药物UBX1325治疗糖尿病性黄斑水肿(DME)的I期临床研究已在美国完成首例患者给药。UBX1325为亚盛医药授权UNITY用于抗衰老领域药物开发的在研化合物Bcl-xL抑制剂BM-962。

该临床进展已触发此前亚盛医药和UNITY达成的许可协议的里程碑付款。根据许可协议条款,亚盛医药有权获得以UNITY普通股形式支付的款项,合计228,310股。UNITY此次开展的临床试验为一项开放的I期临床研究,旨在评估UBX1325在晚期DME患者中的安全性、耐受性和药代动力学。该试验计划纳入约15名患者,预计在2021年上半年获得安全性和耐受性数据。据UNITY发布的公开信息显示, UBX1325在临床前试验中表现出影响衰老细胞、减少血管渗漏、改善视网膜功能的显著能力。

亚盛医药于2016年与UNITY达成战略合作,其中包括关于化合物库的合作协议, UNITY获授权可对亚盛医药的Bcl-2系列化合物进行筛选,以用于在抗衰老领域的开发。UNITY选中BM-962作为用于UBX1325研发的化合物。根据适用协议,亚盛医药拥有该化合物的大中华地区权益,未来计划和UNITY成立合资公司,共同开发中国市场。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account